Your browser doesn't support javascript.
loading
Evaluation and Modification of a Shared Decision-Making Tool for Peanut Allergy Management.
Anagnostou, Aikaterini; Yaworsky, Andrew; Brova, Monica; Ibrahim, Nazifa; Kakked, Siddharth; Spite, Sasha; Duluc, Linette; Shields, Alan L; Lee, Tricia; Leonard, Stephanie; Przywara, Kathy; Smith, Amelia.
Afiliación
  • Anagnostou A; Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.
  • Yaworsky A; Adelphi Values, One Lincoln Street, Suite 2400, Boston, MA, 02111, USA. Andrew.Yaworsky@adelphivalues.com.
  • Brova M; Adelphi Values, One Lincoln Street, Suite 2400, Boston, MA, 02111, USA.
  • Ibrahim N; Adelphi Values, One Lincoln Street, Suite 2400, Boston, MA, 02111, USA.
  • Kakked S; Adelphi Values, One Lincoln Street, Suite 2400, Boston, MA, 02111, USA.
  • Spite S; California State University San Marcos, San Marcos, CA, USA.
  • Duluc L; Adelphi Values, One Lincoln Street, Suite 2400, Boston, MA, 02111, USA.
  • Shields AL; Adelphi Values, One Lincoln Street, Suite 2400, Boston, MA, 02111, USA.
  • Lee T; Emory University School of Medicine, Children's Healthcare of Atlanta, Atlanta, GA, USA.
  • Leonard S; American College of Allergy, Asthma, and Immunology, Arlington Heights, IL, USA.
  • Przywara K; University of California San Diego, San Diego, CA, USA.
  • Smith A; Rady Children's Hospital, San Diego, CA, USA.
Curr Allergy Asthma Rep ; 24(6): 303-315, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38639896
ABSTRACT
PURPOSE OF REVIEW Based on shared decision-making (SDM) principles, a decision aid was previously developed to help patients, their caregivers, and physicians decide which peanut allergy management approach best suits them. This study refined the decision aid's content to better reflect patients' and caregivers' lived experience. RECENT

FINDINGS:

Current standard of care for peanut allergy is avoidance, although peanut oral immunotherapy has been approved by the Food and Drug Administration for use in patients 4-17 years old. An advisory board of allergy therapy experts (n = 3) and patient advocates (n = 3) informed modifications to the decision aid. The revised tool underwent cognitive debriefing interviews (CDIs) among adolescents (12-17 years old) with peanut allergy and caregivers of patients 4-17 years old with peanut allergy to evaluate its relevance, understandability, and usefulness. The 20 CDI participants understood the information presented in the SDM tool and reported it was important and relevant. Some revisions were made based on participant feedback. Results support content validity of the Peanut Allergy Treatment SDM Tool.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hipersensibilidad al Cacahuete / Toma de Decisiones Conjunta Límite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Curr Allergy Asthma Rep Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Hipersensibilidad al Cacahuete / Toma de Decisiones Conjunta Límite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Curr Allergy Asthma Rep Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos